|
1
|
Guo Y and Pei X: Tetrandrine-induced
autophagy in MDA-MB-231 Triple-negative breast cancer cell through
the Inhibition of PI3K/AKT/mTOR signaling. Evid Based Complement
Alternat Med. 20:75174312019.
|
|
2
|
Jin F, Wu Z, Hu X, Zhang J, Gao Z, Han X,
Qin J, Li C and Wang Y: The PI3K/Akt/GSK-3β/ROS/eIF2B pathway
promotes breast cancer growth and metastasis via suppression of NK
cell cytotoxicity and tumor cell susceptibility. Cancer Biol Med.
16:38–54. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nassan MA, Soliman MM, Ismail SA and
El-Shazly S: Effect of Taraxacum officinale extract on PI3K/Akt
pathway in DMBA-induced breast cancer in albino rats. Biosci Rep.
38:BSR201803342018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pascual J and Turner NC: Targeting the
PI3-kinase pathway in triple-negative breast cancer. Ann Oncol.
30:1051–1060. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jouali F, Marchoudi N, Talbi S, Bilal B,
El Khasmi M, Rhaissi H and Fekkak J: Detection of PIK3/AKT pathway
in Moroccan population with triple negative breast cancer. BMC
Cancer. 18:9002018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou T, Xu D, Tang B, Ren Y, Han Y, Liang
G, Wang J and Wang L: Expression of programmed death ligand-1 and
programmed death-1 in samples of invasive ductal carcinoma of the
breast and its correlation with prognosis. Anticancer Drugs.
29:904–910. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sarveazad A, Babahajian A, shamsadin J and
Bahardoust M: 5-year survival rates and prognostic factors in
patients with synchronus and metachronus breast cancer from 2010 to
2015. Asian Pac J Cancer Prev. 19:3489–3493. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fu R, Deng Q, Zhang H, Hu X, Li Y, Liu Y,
Hu J, Luo Q, Zhang Y, Jiang X, et al: A novel autophagy inhibitor
berbamine blocks SNARE-mediated autophagosome-lysosome fusion
through upregulation of BNIP3. Cell Death Dis. 9:2432018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simonetti RG, Camma C, Fiorello F, Politi
F, D'Amico G and Pagliaro L: Hepatocellular carcinoma. A worldwide
problem and the major risk factors. Dig Dis Sci. 36:962–972. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H, Wang Z, Jiang M, Fang RP, Shi H,
Shen Y, Cai XL, Liu Q, Ye K, Fan SJ, et al: The oncoprotein HBXIP
promotes human breast cancer growth through down-regulating p53 via
miR-18b/MDM2 and pAKT/MDM2 pathways. Acta Pharmacol Sin.
39:1787–1796. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu H, Ruan S, Jia F, Chu J, Zhu Y, Huang
Y and Liu G: In vitro and in vivo superior radiosensitizing effect
of berbamine for head and neck squamous cell carcinoma. Onco
Targets Ther. 11:8117–8125. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leal-Orta E, Ramirez-Ricardo J,
Cortes-Reynosa P, Galindo-Hernandez O and Salazar EP: Role of
PI3K/Akt on migration and invasion of MCF10A cells treated with
extracellular vesicles from MDA-MB-231 cells stimulated with
linoleic acid. J Cell Commun Signal. 13:235–244. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian L, Cheng F, Wang L, Qin W, Zou K and
Chen J: CLE-10 from Carpesium abrotanoides L. Suppresses the Growth
of human breast cancer cells (MDA-MB-231) in vitro by inducing
apoptosis and pro-death autophagy via the PI3K/Akt/mTOR signaling
pathway. Molecules. 24:10912019. View Article : Google Scholar
|
|
15
|
Xia E, Zhou X, Bhandari A, Zhang X and
Wang O: Synaptopodin-2 plays an important role in the metastasis of
breast cancer via PI3K/Akt/mTOR pathway. Cancer Manag Res.
10:1575–1583. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan W, Ma X, Zhao X and Zhang S: Baicalein
induces apoptosis and autophagy of breast cancer cells via
inhibiting PI3K/AKT pathway in vivo and vitro. Drug Des Devel Ther.
12:3961–3972. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu
K, Luan J, Duan H, Lu Z, Wang F, et al: Suppression of growth,
migration and invasion of highly-metastatic human breast cancer
cells by berbamine and its molecular mechanisms of action. Mol
Cancer. 8:812009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stephen H and Hare AJ: mTOR function and
therapeutic targeting in breast cancer. Am J Cancer Res. 7:383–404.
2017.PubMed/NCBI
|
|
19
|
Zheng S, Lv P, Su J, Miao K, Xu H and Li
M: Overexpression of CBX2 in breast cancer promotes tumor
progression through the PI3K/AKT signaling pathway. Am J Transl
Res. 11:1668–1682. 2019.PubMed/NCBI
|
|
20
|
Fan L, Zhang Y, Zhou Q, Liu Y, Gong B, Lü
J, Zhu H, Zhu G, Xu Y and Huang G: Casticin inhibits breast cancer
cell migration and invasion by down-regulation of PI3K/Akt
signaling pathway. Biosci Rep. 38:BSR201807382018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pierobon M, Ramos C, Wong S, Hodge KA,
Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb
M, et al: Enrichment of PI3K-AKT-mTOR pathway activation in hepatic
metastases from breast cancer. Clin Cancer Res. 23:4919–4928. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiang P, Shao Y, Sun YP, Zhang J and Chen
LJ: Metformin inhibits proliferation and migration of endometrial
cancer cells through regulating PI3K/AKT/MDM2 pathway. Eur Rev Med
Pharmacol Sci. 23:1778–1785. 2019.PubMed/NCBI
|
|
23
|
Ghoneum A and Said N: PI3K-AKT-mTOR and
NFκB pathways in ovarian cancer: Implications for targeted
therapeutics. Cancers (Basel). 11:9492019. View Article : Google Scholar
|
|
24
|
Qin JJ, Wang W and Zhang R: Experimental
therapy of advanced breast cancer: Targeting NFAT1-MDM2-p53
pathway. Prog Mol Biol Transl Sci. 151:195–216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rinaldi L, Sepe M, Delle Donne R, Conte K,
Arcella A, Borzacchiello D, Amente S, De Vita F, Porpora M, Garbi
C, et al: Mitochondrial AKAP1 supports mTOR pathway and tumor
growth. Cell Death Dis. 8:e28422017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshikawa Y, Takano O, Kato I, Takahashi
Y, Shima F and Kataoka T: Ras inhibitors display an anti-metastatic
effect by downregulation of lysyl oxidase through inhibition of the
Ras-PI3K-Akt-HIF-1α pathway. Cancer Lett. 410:82–91. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Qu P, Zhao H, Zhao T and Cao N:
COX2 promotes epithelialmesenchymal transition and migration in
osteosarcoma MG63 cells via PI3K/AKT/NF-κB signaling. Mol Med Rep.
20:3811–3819. 2019.PubMed/NCBI
|
|
28
|
Chan N, Willis A, Kornhauser N, Ward MM,
Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, et al:
Influencing the tumor microenvironment: A phase II study of copper
depletion using tetrathiomolybdate in patients with breast cancer
at high risk for recurrence and in preclinical models of lung
metastases. Clin Cancer Res. 23:666–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mosalpuria K, Hall C, Krishnamurthy S,
Lodhi A, Hallman DM, Baraniuk MS, Bhattacharyya A and Lucci A:
Cyclooxygenase-2 expression in non-metastatic triple-negative
breast cancer patients. Mol Clin Oncol. 2:845–850. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Du HP, Shen JK, Yang M, Wang YQ, Yuan XQ,
Ma QL and Jin J: 4-Chlorobenzoyl berbamine induces apoptosis and
G2/M cell cycle arrest through the PI3K/Akt and NF-kappaB signal
pathway in lymphoma cells. Oncol Rep. 23:709–716. 2010.PubMed/NCBI
|
|
31
|
Zhang L, Tong J, He X, Liang Y, Zhu L, Xu
R and Zhao X: Novel synthetic 4-chlorobenzoyl berbamine inhibits
c-Myc expression and induces apoptosis of diffuse large B cell
lymphoma cells. Ann Hematol. 97:2353–2362. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang SS, Lv Y, Xu XC, Zuo Y, Song Y, Wu
GP, Lu PH, Zhang ZQ and Chen MB: Triptonide inhibits human
nasopharyngeal carcinoma cell growth via disrupting Lnc-RNA
THOR-IGF2BP1 signaling. Cancer Lett. 443:13–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cummins CB, Wang X, Xu J, Hughes BD, Ding
Y, Chen H, Zhou J and Radhakrishnan RS: Antifibrosis effect of
novel oridonin analog CYD0618 via suppression of the NF-κB pathway.
J Surg Res. 232:283–292. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saatci O, Kaymak A, Raza U, Ersan PG,
Akbulut O, Banister CE, Sikirzhytski V, Tokat UM, Aykut G, Ansari
SA, et al: Targeting lysyl oxidase (LOX) overcomes chemotherapy
resistance in triple negative breast cancer. Nat Commun.
11:24162020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meng F, Wu L, Dong L, Mitchell AV, James
Block C, Liu J, Zhang H, Lu Q, Song WM, Zhang B, et al: EGFL9
promotes breast cancer metastasis by inducing cMET activation and
metabolic reprogramming. Nat Commun. 10:50332019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu R, Zhang Y, Chen Y, Qi J, Ren S, Xushi
MY, Yang C, Zhu H and Xiong D: A novel calmodulin antagonist
O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in
drug-resistant MCF-7/ADR breast carcinoma cells. J Pharm Sci.
99:3266–3275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cao Y, Cao J, Yu B, Wang S, Liu L, Tao L
and Sun W: Berbamine induces SMMC-7721 cell apoptosis via
upregulating p53, downregulating survivin expression and activating
mitochondria signaling pathway. Exp Ther Med. 15:1894–1901.
2018.PubMed/NCBI
|
|
38
|
Jin X and Wu Y: Berbamine enhances the
antineoplastic activity of gemcitabine in pancreatic cancer cells
by activating transforming growth factor-β/Smad signaling. Anat Rec
(Hoboken). 297:802–809. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao Y, Lv JJ, Chen J, Jin XB, Wang MW, Su
ZH, Wang LY and Zhang HY: Berbamine inhibited the growth of
prostate cancer cells in vivo and in vitro via triggering intrinsic
pathway of apoptosis. Prostate Cancer Prostatic Dis. 19:358–366.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ding X, Wang Q, Tong L, Si X and Sun Y:
Long non-coding RNA FOXO1 inhibits lung cancer cell growth through
down-regulating PI3K/AKT signaling pathway. Iran J Basic Med Sci.
22:491–498. 2019.PubMed/NCBI
|
|
41
|
Deng S, Dai G, Chen S, Nie Z, Zhou J, Fang
H and Peng H: Dexamethasone induces osteoblast apoptosis through
ROS-PI3K/AKT/GSK3β signaling pathway. Biomed Pharmacother.
110:602–608. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Leszczynska KB, Foskolou IP, Abraham AG,
Anbalagan S, Tellier C, Haider S, Span PN, O'Neill EE, Buffa FM and
Hammond EM: Hypoxia-induced p53 modulates both apoptosis and
radiosensitivity via AKT. J Clin Invest. 125:2385–2398. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yue X, Li M, Chen D, Xu Z and Sun S:
UNBS5162 induces growth inhibition and apoptosis via inhibiting
PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231
cells. Exp Ther Med. 16:3921–3928. 2018.PubMed/NCBI
|
|
44
|
Wang W, Wu J, Fei X, Chen W, Li Y, Shen K
and Zhu L: CHD1L promotes cell cycle progression and cell motility
by up-regulating MDM2 in breast cancer. Am J Transl Res.
11:1581–1592. 2019.PubMed/NCBI
|
|
45
|
Liu XH, Kirschenbaum A, Yu K, Yao S and
Levine AC: Cyclooxygenase-2 suppresses hypoxia-induced apoptosis
via a combination of direct and indirect inhibition of p53 activity
in a human prostate cancer cell line. J Biol Chem. 280:3817–3823.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gao S, Li X, Ding X, Qi W and Yang Q:
Cepharanthine induces autophagy, apoptosis and cell cycle arrest in
breast cancer cells. Cell Physiol Biochem. 41:1633–1648. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Haginaka J, Kitabatake T, Hirose I,
Matsunaga H and Moaddel R: Interaction of cepharanthine with
immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α
inhibitors. Anal Biochem. 434:202–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bailly C: Cepharanthine: An update of its
mode of action, pharmacological properties and medical
applications. Phytomedicine. 62:1529562019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim BR, Dong SM, Seo SH, Lee JH, Lee JM,
Lee SH and Rho SB: Lysyl oxidase-like 2 (LOXL2) controls
tumor-associated cell proliferation through the interaction with
MARCKSL1. Cell Signal. 26:1765–1773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Y, Sun H, Xiao Z, Zhang G, Zhang D,
Bao X, Li F, Wu S, Gao Y and Wei N: DNA damage and apoptosis
induced by a potent orally podophyllotoxin derivative in breast
cancer. Cell Commun Signal. 16:522018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kanaizumi H, Higashi C, Tanaka Y, Hamada
M, Shinzaki W, Azumi T, Hashimoto Y, Inui H, Houjou T and Komoike
Y: PI3K/Akt/mTOR signalling pathway activation in patients with
ER-positive, metachronous, contralateral breast cancer treated with
hormone therapy. Oncol Lett. 17:1962–1968. 2019.PubMed/NCBI
|
